-
LLM student at a reputable law school, outstanding LLB student is welcomed
国内知名法学院硕士研究生在读，优秀的在读本科生
-
Overseas exchange programme experience is preferred
有过海外交流学习经验的优先考虑
-
Internship experience with reputable law firms is preferred
知名律所实习经验优先考虑
-
Passed the PRC national judicial examination is preferred
通过国家司法考试的优先考虑
-
Excellent written and spoken English and Mandarin
英文听说读写能力优秀，中文文字表达能力优秀
-
Detail-oriented, be proactive
工作细致严谨、积极主动
-
Communicates in a clear and concise manner
沟通清晰明了
-
Great chance to retention if excellent
非常大的留用机会如果你足够优秀
-
Involvement into each stage of capital market transactions under the guidance and supervision
-
Assist on the legal research, due diligence and legal issue analysis
-
Assist on the drafting/review of the offering documents and transaction documents
在律师的指导和监督下参与资本市场交易各个阶段的工作
协助法律检索，尽职调查及法律事项分析
协助发行及交易文件的起草及审阅
Our Greater China capital markets team is equipped to provide full legal services in both debt and equity capital markets with a strong track record of advising issuers and underwriters on public offerings and private placements of debt and equity across a wide range of industry sectors.
Our ECM practice have advised many high profile and "first of its kind" IPOs including unprecedented spin-off listings, A to H listings, and simultaneous A and H dual listings. Our extensive experience in dealing with complex legal structures and technical issues helps our clients to get the deal through. We also have a US securities capability which provides support on US securities laws and liability issues. The combination of our technical excellence, reliability and customer centric approach allows us to provide an all rounded high quality service experience to our clients.
Herbert Smith Freehills has advised on a number of biotech listings since the Hong Kong Stock Exchange introduced its new regime for biotech listings in 2018, including those of Biocytogen Pharmaceuticals (02315.HK), Rainmed Medical Limited (02297.HK), Lepu Biopharma (02157.HK), Shanghai Bio-heart (02185.HK), Abbisko Cayman Limited (02256.HK), Acotec Scientific Holdings Limited (06669.HK), Shanghai HeartCare Medical Technology (06609.HK), Brii Biosciences (02137.HK), CARsgen Therapeutics (02171.HK), Antengene Corporation Limited (06996.HK), Peijia Medical (09996.HK), SinoMab BioScience Limited (03681.HK), TOT BIOPHARM (01875.HK) and Shanghai Junshi Biosciences (01877.HK). In 2022, the firm has advised on eleven successful listings in Hong Kong. Notably, Herbert Smith Freehills has advised Onewo Inc. (02602.HK), Lygend Resources & Technology Co., Ltd. (02245.HK), and JL MAG Rare-Earth Co., Ltd. (06680.HK), respectively the 4th, 6th and 7th largest IPO.
Please send your CV in both English and Chinese versions, transcript and writing samples in both English and Chinese versions to application.asiarecruitment@hsf.com . Please indicate the applied position in the subject and the internship period.
史密夫斐尔是全球领先的律师事务所，在亚太地区、欧洲、中东、非洲和北美设有二十多家办公室，深入全球新商业格局的核心。我们拥有约2600位律师，洞悉了解各个市场，纵深众多行业领域，依靠专业知识和本地智慧，为客户提供全方位的法律服务。
本所根植中国市场40余年，在北京、上海、香港三个办公室拥有强有力的律师团队，对中国的商业文化有着细致深入的体会和理解，为客户提供高效、优质的全方位法律服务。
史密夫斐尔与上海市自贸区的科伟律师事务所正式联营，通过科伟史密夫斐尔联营办公室 (Herbert Smith Freehills Kewei (FTZ) Joint Operation) 提供中国法及外国法服务。
